Buy Desogestrel and Ethinyl estradiol

Desogestrel and Ethinyl estradiol

Desogestrel and Ethinyl estradiol: Women's Health Overview

Desogestrel and ethinyl estradiol are the active ingredients in a combined oral contraceptive (COC) pill. The formulation is marketed in the United Kingdom as a prescription-only medication and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is intended for menstrual cycle regulation and reliable contraception in adult women of reproductive age.

How Desogestrel and Ethinyl estradiol Work in the Body

• Estrogen component (ethinyl estradiol) - a synthetic form of the natural hormone estradiol. It binds to estrogen receptors in the uterus, cervix and breast, stabilising the endometrial lining and reducing menstrual-related bleeding.
• Progestin component (desogestrel) - a third-generation progestogen that binds to progesterone receptors. It thickens cervical mucus, making it difficult for sperm to penetrate, and suppresses the mid-cycle luteinising hormone (LH) surge, preventing ovulation.
• Combined effect - The two hormones work synergistically to inhibit ovulation, alter the uterine environment, and keep the endometrium thin, providing effective contraception. Onset of action occurs within the first 7 days of consistent daily dosing, with a typical cycle length of 21 days of active pills followed by a 7-day pill-free interval.

Conditions Treated by Desogestrel and Ethinyl estradiol

• Contraception - Primary, FDA- and MHRA-approved indication for preventing pregnancy when taken as directed.
• Menstrual regulation - Provides cycle control, reduces heavy or irregular bleeding, and can improve dysmenorrhoea.
• Acne improvement (off-label) - Some clinicians prescribe COCs containing desogestrel for moderate acne, although this use is not formally approved in the UK. Off-label use should be discussed with a healthcare professional.

Patient Suitability and Contraindications

Who Should Use This Pill?

• Women of reproductive age seeking reliable, reversible contraception.
• Patients without a history of estrogen-dependent neoplasia, thromboembolic disorders, or uncontrolled hypertension.

Absolute Contraindications

• Known or suspected pregnancy.
• History of or current deep vein thrombosis (DVT), pulmonary embolism, or other thromboembolic disorders.
• History of coronary artery disease, stroke, or myocardial infarction.
• Active or past hormone-dependent cancers (e.g., breast, endometrial).
• Uncontrolled hypertension (≥ 160/100 mmHg).
• Severe liver disease (e.g., hepatitis, cirrhosis).
• Known hypersensitivity to desogestrel, ethinyl estradiol, or any excipient in the pill.

Relative Contraindications

• Smoking in women over 35 years (increased cardiovascular risk).
• Migraine with aura.
• Diabetes with vascular complications.
• Chronic kidney disease requiring dialysis.

Special Populations

• Pregnancy and lactation - Contraindicated during pregnancy; breastfeeding women should discuss alternative methods, as estrogen can reduce milk production.
• Post-menopausal women - Not indicated.
• Adolescents - May be prescribed after careful assessment of risk factors, particularly for thrombotic events.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or mild gastrointestinal upset.
• Breast tenderness or enlargement.
• Spotting or breakthrough bleeding, especially during the first 3 months.
• Headache or mild migraine.
• Mood changes, including mild irritability.

Serious Adverse Events

• Venous thromboembolism (VTE) - Rare but potentially life-threatening; signs include calf pain, swelling, or sudden shortness of breath.
• Arterial thrombosis - May present as chest pain, stroke symptoms, or sudden visual loss.
• Hepatic adenoma - Very uncommon, usually detected incidentally on imaging.
• Hypertensive crisis - Severe headache, visual disturbances, or chest pain in patients with uncontrolled blood pressure.

Drug Interactions

• Major:

• Enzyme inducers (e.g., rifampicin, carbamazepine, phenytoin) can lower hormone levels, reducing contraceptive efficacy.

• Antiretrovirals (e.g., efavirenz) may also diminish effectiveness.

• Moderate:

• Antifungals (ketoconazole) and some antibiotics (clarithromycin, erythromycin) may increase plasma estrogen levels, potentially heightening side-effect risk.

• Mechanism: Many interactions involve induction or inhibition of the CYP3A4 enzyme pathway, which metabolises both desogestrel and ethinyl estradiol.

Food and Lifestyle Interactions

• Grapefruit juice - Can increase estrogen exposure by inhibiting CYP3A4; limit excessive intake.
• Alcohol - Moderate consumption does not affect efficacy, but excessive intake may increase liver strain.
• Driving/Machinery - No direct impairment, though dizziness or severe headache may transiently affect performance.

How to Take Desogestrel and Ethinyl estradiol

• Standard regimen: One pill daily for 21 consecutive days, followed by a 7-day pill-free interval during which withdrawal bleeding occurs. Each pill contains 150 µg (0.15 mg) desogestrel and 30 µg ethinyl estradiol.
• Administration: Swallow the tablet whole with water; it may be taken with or without food. Consistency in timing (same hour each day) helps maintain steady hormone levels.
• Missed dose:
• If a pill is missed by less than 12 hours, take it as soon as remembered and continue the pack.
• If missed by more than 12 hours, take the missed pill immediately, discard any subsequent pills in the pack, start a new pack the following day, and use a backup barrier method for the next 7 days.
• Special populations:
• Renal or hepatic impairment - No routine dose adjustment, but clinicians may monitor more closely for adverse effects.
• Elderly women - Generally not prescribed unless clear benefit outweighs risk.
• Overdose: Symptoms may include nausea, vomiting, breast tenderness, and severe headache. Seek immediate medical attention; activated charcoal may be considered if presentation is early.
• Discontinuation: The pill can be stopped at any time. No tapering is required, but a backup method should be used for 7 days if contraception is still desired.

Monitoring and Follow-Up

• Initial assessment: Blood pressure, smoking status, migraine history, and liver function tests.
• Routine follow-up: Annual blood pressure check and review of any new symptoms (e.g., leg swelling, visual changes).
• Lab tests: Not required for most users; however, clinicians may order liver function panels or lipid profiles if clinically indicated.

Storage and Handling

• Store at room temperature (15 °C-30 °C) in a dry place, away from direct sunlight and moisture.
• Keep out of reach of children; the packaging includes a child-resistant blister pack.
• Do not use tablets after the expiry date printed on the pack.

Medication-Specific Glossary

Combined Oral Contraceptive (COC)

A tablet that contains both an estrogen and a progestin, designed to prevent ovulation and induce cervical mucus changes.

Progestin

A synthetic analogue of progesterone; desogestrel is a third-generation progestin that provides strong anti-ovulatory activity.

Estrogenic Component

Ethinyl estradiol mimics natural estrogen, maintaining the endometrial lining and contributing to cycle control.

Venous Thromboembolism (VTE)

Formation of a blood clot in a vein, which can travel to the lungs (pulmonary embolism). Hormonal contraception modestly increases this risk.

Contraindication

A specific situation where a drug should not be used because the risk of harm outweighs any potential benefit.

Medical Disclaimer

This article provides educational information about desogestrel and ethinyl estradiol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.